Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Total Non-Current Liabilities (2016 - 2024)

Voyager Therapeutics' Total Non-Current Liabilities history spans 10 years, with the latest figure at $56.4 million for Q3 2024.

  • For Q3 2024, Total Non-Current Liabilities fell 43.36% year-over-year to $56.4 million; the TTM value through Sep 2024 reached $56.4 million, down 43.36%, while the annual FY2023 figure was $96.9 million, 22.55% up from the prior year.
  • Total Non-Current Liabilities for Q3 2024 was $56.4 million at Voyager Therapeutics, down from $59.6 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $211.8 million in Q1 2020 and bottomed at $56.3 million in Q3 2021.
  • The 5-year median for Total Non-Current Liabilities is $80.6 million (2022), against an average of $91.5 million.
  • The largest annual shift saw Total Non-Current Liabilities crashed 72.44% in 2021 before it skyrocketed 88.68% in 2022.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $62.9 million in 2020, then decreased by 5.83% to $59.2 million in 2021, then soared by 33.54% to $79.0 million in 2022, then grew by 22.55% to $96.9 million in 2023, then crashed by 41.81% to $56.4 million in 2024.
  • Per Business Quant, the three most recent readings for VYGR's Total Non-Current Liabilities are $56.4 million (Q3 2024), $59.6 million (Q2 2024), and $85.7 million (Q1 2024).